Evidence map›Paper›PMID 42033344›Full record

ArticleJournal of chemical information and modeling2026

A Transformer for Reaction-Aware Compound Explorations with GFlowNet in QSAR-Guided Molecular Design.

Shogo Nakamura, Nobuaki Yasuo, Masakazu Sekijima

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shogo NakamuraDepartment of Life Science and Technology, Institute of Science Tokyo, Midori-ku, Yokohama 226-8501, Japan.ORCID 0009-0003-6071-2755
Nobuaki YasuoTokyo Tech Academy for Convergence of Materials and Informatics (TAC-MI), Institute of Science Tokyo, Meguro-ku, Tokyo 152-8550, Japan.ORCID 0000-0002-3114-7895
Masakazu SekijimaDepartment of Computing, Institute of Science Tokyo, Midori-ku, Yokohama 226-8501, Japan.ORCID 0000-0002-3806-9535

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In drug discovery tasks, achieving a balance between high biological activity toward therapeutic targets and synthetic chemical feasibility is critically important. While the recently proposed deep learning-based molecular generation models have enabled explorations of vast chemical spaces, most existing approaches do not consider synthetic routes for generated compounds. To address this issue, TRACE-GFN is proposed for molecular optimization; this method incorporates chemical reaction pathways into a quantitative structure-activity relationship (QSAR)-guided molecular design procedure. The method integrates a transformer model to explicitly learn chemical reactions with a generative flow network (GFlowNet) that efficiently samples diverse candidates. In benchmark experiments involving dopamine receptor D2 (DRD2), AKT serine/threonine kinase 1 (AKT1), and C-X-C motif chemokine receptor 4 (CXCR4), TRACE-GFN demonstrated the ability to identify compounds with high QSAR values while maintaining strong diversity, outperforming the existing molecular generation models. These results demonstrate that the proposed model can efficiently explore promising compounds while accounting for real-world chemical reactions. The source code is publicly available under an MIT license at https://github.com/sekijima-lab/TRACE-GFN.

Indexed as

Deep LearningDrug DesignQuantitative Structure-Activity RelationshipModels, MolecularProto-Oncogene Proteins c-aktReceptors, CXCR4Receptors, Dopamine D2Proto-Oncogene Proteins c-aktReceptors, CXCR4Receptors, Dopamine D2

Identifiers

PMID42033344
PMCPMC13169345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.